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Immature Rat Uterotrophic Assay of Bisphenol A
Kanji Yamasaki, Masakuni Sawaki, and Mineo Takatsuki
Chemicals Assessment Center, Chemicals Evaluation and Research Institute, Oita, Japan 
There is concern that certain chemicals may
have the potential to disturb normal sexual
differentiation and development in animals
and humans (1,2). Recently, the Organi-
sation for Economic Co-operation and
Development (OECD) proposed the
immature rat uterotrophic assay as one
screening method for detecting the estro-
genic properties of such chemicals, in which
the chemical compounds are orally or sub-
cutaneously administered for 3 days (3).
Bisphenol A (BPA) has been conﬁrmed
to have weak estrogenicity in vitro that is
approximately 15,000 times less potent than
17 β -estradiol and interacts with both the α -
and β -estrogen receptors (4–7). It is an
important chemical used principally as a
monomer in the manufacture of a multitude
of chemical products including epoxy resins
and polycarbonate, and its output has gradu-
ally increased from year to year. Uterotrophy
measured by uterotrophic assay of BPA in
the immature rat was previously detected
after subcutaneous (sc) or oral administra-
tion of 400 mg/kg BPA (8), whereas no
uterotrophy in this assay was observed in rats
orally administered 5–150 mg/kg BPA (9).
However, this assay has not yet been used to
determine the lowest dose of BPA that can
induce a uterotrophic response.
One purpose of this study was to deter-
mine the estrogenic effect of BPA at low dose
levels using the immature rat uterotrophic
assay. We also measured the plasma concen-
trations of BPA 1 hr after the last administra-
tion to examine the differences in plasma
concentrations between sc and oral adminis-
tration routes. 
Because the reproducibility of the
uterotrophic assay has been questioned (10),
we performed a repeat study of BPA with the
immature rat uterotrophic assay. Although
time-course changes in uterine weight in the
immature rat uterotrophic assay have been
reported after the last administration of strong
estrogenic compounds such as 17β -estradiol
(11), there have been no reports of weak
estrogenic compounds using this assay. By
comparison, the OECD proposed autopsy in
the immature rat uterotrophic assay at 24 hr
after the last administration. Therefore, our
other purpose in this study was to examine
the time-course changes of uterine weight in
the immature rat uterotrophic assay of BPA.
Materials and Methods
Study 1 
Chemicals. We purchased BPA (lot
077H0666; > 98% pure) from Kanto
Chemical Co., Tokyo, Japan, and sesame oil
(lot 004RYY) from Fujimi Pharmaceutical,
Co., Osaka, Japan.
Animals. Pregnant Crj:CD (SD) rats (at
day 14 of gestation) were purchased from
Charles River Japan, Inc., Shiga, Japan. At
postnatal day (PND) 4, the litters were
culled to eight per dam, and dams and pups
were kept in polycarbonate pens until wean-
ing. All rats were weaned at PND 17 and
then housed individually in stainless steel
wire-mesh cages during the study. The
immature rats were weighed, weight-ranked,
and assigned randomly to each of the treat-
ment and control groups; each group con-
sisted of 10 rats. Body weights and clinical
signs were recorded on a daily basis through-
out the study. Before weaning, rats were pro-
vided with tap water and a commercial diet
(CRF-1; Oriental Yeast Co., Tokyo, Japan)
ad libitum; after weaning, rats received water
automatically and a commercial diet (MF;
Oriental Yeast Co., Tokyo, Japan) ad libi-
tum. The animal room was maintained at a
temperature of 23 ± 20°C and a relative
humidity of 55 ± 5%, and was artificially
illuminated with ﬂuorescent light on a 12-hr
light/dark cycle (0600–1800 hr).
All animals were cared for according to
the principles outlined in the guide for animal
experimentation prepared by the Japanese
Association for Laboratory Animal Science. 
Study design. BPA (in sesame oil) was
injected sc at 8, 40, and 160 mg/kg for 3
days beginning on PND 18, or administered
orally via a stomach tube at 40, 160, and
800 mg/kg for 3 days beginning on PND
18. These doses were based on the results of
preliminary studies using sc or oral doses of
40, 160, and 800 mg/kg/day. The concen-
tration and stability of BPA were conﬁrmed.
Rats were administered 2 mL/kg body
weight of sesame oil containing BPA sc or 5
mL/kg orally. A vehicle control group given
only sesame oil was also established for each
administration route. The animals were
killed approximately 24 hr after the last
administration by bleeding from the abdom-
inal vein under deep ether anesthesia. After
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Articles
We used the immature rat uterotrophic assay to determine the estrogenicity of bisphenol A (BPA).
We administered BPA (in sesame oil) to rats subcutaneously (sc; 0, 8, 40, and 160 mg/kg/day) or
orally (0, 40, 160, and 800 mg/kg/day) for 3 days beginning on postnatal day (PND) 18; rats were
sacriﬁced 24 hr after the last administration. Uterine wet, blotted, and relative weights increased in all
groups given BPA sc. After oral administration, uterine relative weight increased in 160 and 800
mg/kg BPA groups, and wet and blotted weights increased in the 800 mg/kg BPA group. Plasma
concentrations of BPA at 1 hr after the last administration were detected in all groups given BPA sc
and in groups given 160 and 800 mg/kg BPA orally, with a dose–response effect. The study was then
reproduced under the same conditions. After sc injections, uterine wet and blotted weights increased
in the 40 and 160 mg/kg BPA groups, and relative weight increased in all groups given BPA sc. By
contrast, uterine wet, blotted, and relative weights increased only in the 160 and 800 mg/kg oral BPA
groups. Also, to examine time-course changes in uterine weight, we administered BPA (in sesame oil)
sc from PND 18 to PND 20 for 3 days at doses of 0, 8, 40, and 160 mg/kg/day; uterine weights were
then measured at 6, 12, 18, and 24 hr after the last administration. Uterine wet, blotted, and relative
weights increased in all BPA groups at 6 and 24 hr and in 40 and 160 mg/kg BPA groups at 12 hr.
By contrast, at 18 hr, uterine wet, blotted, and relative blotted weights increased in all BPA groups
and relative wet weight increased in 40 and 160 mg/kg BPA groups. The percentage increases in
uterine wet and relative weights of 40 and 160 mg/kg BPA groups at 6 hr were higher than those at
24 hr relative to the controls, but the coefﬁcient of variation in these weights in the group given 8
mg/kg BPA at 24 hr was smaller than that at 6 hr. These findings demonstrate BPA-induced
uterotrophy in the immature uterotrophic assay in rats administered 8 mg/kg/day sc and in rats given
160 mg/kg/day orally, and suggest that the autopsy at 24 hr after the last administration is suitable.
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free of adhering fat and mesentery and then
weighed. Plasma concentrations of BPA
were measured in four female rats from each
group 1 hr after the last administration. The
time sampling point was determined by the
results of preliminary study: mean plasma
concentration of three rats given 1,000
mg/day BPA subcutaneously or orally for 3
days was higher 1 hr after the last adminis-
tration than that at 0.5, 2, 4 and 6 hr after
administration. 
Plasma samples of each group were pre-
treated by solid extraction column and then
measured using HPLC. Plasma samples (250
µL) were applied to the Sep-Pak C18
Cartridge (6 cc, 1 g, part WAT036905;
Waters, Milford, MA, USA), washed twice
with 1 mL distilled water and 1 mL 20%
acetonitrile, and eluted with 500 µL 70%
acetonitrile. A 20 µL aliquot of the efﬂuent
was analyzed using an HPLC system consist-
ing of a pump (model L-7100; Hitachi,
Tokyo, Japan), an auto sampler (model L-
7200; Hitachi), a column oven (model L-
7300; Hitachi), a detector (model L-7480
FL; Hitachi), and a D-7000 HPLC system
manager (Hitachi). An L-column ODS (4.6
mm i.d. ×  250mm; Chemicals Evaluation
and Research Institute, Tokyo, Japan) was
used for the analysis. For the mobile phase,
we used 43% acetonitrile in water and a ﬂow
rate of 1 mL/min. Detection was performed
at 224 nm (excitation wavelength) and 310
nm (emission wavelength).
Statistical analysis. Data of body weight
and uterine weight were tested by Bartlett’s
test for homogeneity of variance. When the
homogeneity of variance (p < 0.05) was evi-
dent from Bartlett’s test, we performed
analysis of variance (ANOVA). When signif-
icant (p < 0.05) treatment differences were
indicated by ANOVA, we used the Student’s
t-test to compared each BPA group with the
control.
Study 2
We performed a repeat test (study 2)
approximately 1 month after study 1 using
the same conditions as for study 1 except
that plasma concentrations were not
measured.
Study 3
For study 3, we used subcutaneous injection
as the only administration route for this
study, after the results of studies 1 and 2
revealed that sensitivity to sc-administered
BPA was higher than with oral administra-
tion. We used the same conditions as for
study 1, except the animals were sacriﬁced at
6, 12, 18, and 24 hr after the last adminis-
tration by bleeding from the abdominal vein
under deep ether anesthesia. 
Results
Study 1 
Clinical signs, body weight, and gross ﬁnd-
ings. We detected no abnormal clinical signs,
including immature vaginal opening or gross
ﬁndings. We also found no signiﬁcant differ-
ences in body weight between the controls
and each BPA group (Table 1). 
Organ weights. Uterine wet, blotted, and
relative weights were increased in all groups
given BPA sc. With oral administration,
however, uterine wet and blotted weights
were increased in the 800 mg/kg BPA group,
whereas relative weight increased in the 160
and 800 mg/kg BPA groups (Table 2).
Plasma concentrations. Plasma concen-
trations of BPA were detected in all groups
given BPA sc and in groups given 160 and
800 mg/kg BPA orally, with a dose–response
effect (Table 3). Comparing plasma concen-
trations for the same dose between sc and
oral routes, BPA values were much higher in
the 160 mg/kg BPA sc group than in the
group given the same dose of BPA orally.
Study 2 
Clinical signs, body weight, and gross ﬁndings.
No abnormal clinical signs were detected, and
there were no signiﬁcant differences in body
weight between the controls and each BPA
group (Table 1).
Uterine weight. With sc injection, uter-
ine wet and blotted weights increased in 40
and 160 mg/kg BPA groups, whereas rela-
tive weights increased in all groups given
BPA. With oral administration, uterine wet,
blotted, and relative weights increased in
groups given 160 and 800 mg/kg BPA orally
(Table 2).
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Table 1. Body weight of rats administered BPA for 3 days beginning on PND 18.
Start weight Final weight
Route/study Dose (mg/kg) (g) (g)
Subcutaneous
Study 1 Vehicle control 36.8 ± 2.1 47.4 ± 2.5
8 36.3 ± 2.2 46.1 ± 2.6
40 36.7 ± 2.2 45.8 ± 2.3
160 36.6 ± 2.0 45.4 ± 2.2
Study 2 Vehicle control 36.9 ± 1.2 47.5 ± 1.9
8 37.4 ± 1.8 46.5 ± 1.8
40 37.0 ± 1.0 46.8 ± 2.3
160 37.1 ± 1.3 44.7 ± 3.3
Oral 
Study 1 Vehicle control 37.1 ± 2.6 46.5 ± 6.3
40 36.5 ± 1.6 45.3 ± 2.2
160 36.1 ± 2.2 45.4 ± 2.8
800 37.1 ± 1.9 45.1 ± 4.5
Study 2 Vehicle control 36.9 ± 1.1 46.6 ± 2.3
40 37.8 ± 1.1 47.2 ± 1.8
160 36.8 ± 1.5 46.2 ± 3.7
800 37.4 ± 1.5 44.5 ± 1.9
Values shown are mean ± SD. 
Table 2. Uterine weight of rats administered BPA for 3 days beginning on PND 18.
Wet Blotted Relative  wet  Relative  blotted
Dose weight weight weight weight
Route/study (mg/kg/day) (mg) (mg) (mg/100g) (mg/100g)
Subcutaneous
Study 1 Vehicle control 27.1 ± 3.6 26.5 ± 3.7 57.2 ± 6.4 55.8 ± 6.7
8 31.1 ± 3.6* 30.3 ± 3.5* 67.8 ± 10.4* 66.1 ± 9.7*
40 39.5 ± 4.6** 38.6 ± 4.4** 86.2 ± 8.7** 84.2 ± 8.4**
160 55.7 ± 10.5** 54.7 ± 10.3** 122.1 ± 18.9** 119.8 ± 18.7**
Study 2 Vehicle control 27.6 ± 2.8 27.0 ± 2.5 58.4 ± 7.0 57.1 ± 6.4
8 31.0 ± 4.5 30.4 ± 4.4 66.6 ± 8.3* 65.2 ± 8.2*
40 40.7 ± 4.2** 39.7 ± 4.0** 87.1 ± 8.2** 84.8 ± 7.6**
160 58.4 ± 8.5** 57.4 ± 8.0** 131.1 ± 21.1** 129.0 ± 20.0**
Oral
Study 1 Vehicle control 27.7 ± 5.2 27.1 ± 5.1 59.5 ± 7.2 58.2 ± 7.3
40 27.1 ± 2.5 26.4 ± 2.3 59.9 ± 6.0 58.4 ± 5.7
160 30.5 ± 2.5 29.8 ± 2.6 67.3 ± 6.1* 65.8 ± 6.0*
800 40.0 ± 6.6** 39.1 ± 6.7** 89.0 ± 14.6** 87.1 ± 14.4**
Study 2 Vehicle control 27.7 ± 3.0 27.1 ± 3.0 59.5 ± 6.0 58.2 ± 5.7
40 29.8 ± 4.8 29.0 ± 4.8 63.1 ± 9.0 61.3 ± 9.2
160 31.9 ± 5.1* 31.0 ± 5.1* 69.1 ± 10.3* 67.4 ± 10.2*
800 41.0 ± 4.0** 39.9 ± 4.0** 92.2 ± 8.3** 89.5 ± 8.1**
Values shown are mean ± SD. 
*Signiﬁcantly different from corresponding vehicle control at p < 0.05. **Signiﬁcantly different from corresponding vehicle
control at p < 0.01.Study 3 
Clinical signs, body weight, and gross ﬁnd-
ings. In study 3, we observed no abnormali-
ties in clinical signs, including immature
vaginal opening and gross ﬁndings. In con-
trast, there were no signiﬁcant differences in
body weight between the control group and
each BPA group.
Uterine weight. Uterine wet, blotted, and
relative weights increased in all BPA groups at
6 or 24 hr after the last administration; these
weights also increased in the 40 and 160
mg/kg BPA groups at 12 hr (Tables 4 and 5).
At 18 hr, uterine wet, blotted, and relative
blotted weights were increased in all BPA
groups, whereas relative wet weight increased
in 40 and 160 mg/kg BPA groups. Although
the percentage increases in uterine wet and rel-
ative weights of the 40 and 160 mg/kg BPA
groups were higher at 6 hr after the last
administration than at 24 hr, the coefﬁcient of
variation in these weights in the 8 mg/kg BPA
group was smaller at 24 hr than at 6 hr.
Discussion
In the immature rat uterotrophic assay, uter-
ine weight has been used as a sensitive para-
meter for evaluating estrogenic activity
(12,13). The OECD has proposed uterine
weight change as an end point of estrogenic
activity (3). Our results conﬁrmed that uter-
ine weight is a good marker for evaluating
the estrogenic activity of BPA. We did not
use parameters such as luminal cell height
and cell proliferation because the usefulness
of these parameters is unclear. Uterotrophy
caused by 400 mg/kg BPA, either sc or oral
administration, has been detected by the
immature rat uterotrophic assay (8), but such
a change has not yet been established for low
doses. The present ﬁndings demonstrate that
rats given a low dose of BPA, such as 8
mg/kg, show the endocrine-disrupting effect.
In studies 1 and 2, uterotrophy was esti-
mated by both wet and relative weight
changes, and reproducibility of the immature
rat uterotrophic assay of BPA was conﬁrmed.
In study 2, uterine wet and blotted weights
increased in groups administered 40 and 160
mg/kg BPA sc and in groups administered
160 and 800 mg/kg BPA orally, whereas in
study 1 these weights increased in all sc BPA
groups and in the group given 800 mg/kg
BPA orally. Uterotrophy in the immature
rat uterotrophic assay was usually deter-
mined by the change in wet weight because
this weight was almost totally uninﬂuenced
by the body weight changes (14,15).
Because there were differences in uterine
wet weights between studies 1 and 2,
uterotrophy may be better estimated by
changes in both wet weight and relative
weight. 
That uterotrophic activity was more sen-
sitive to sc injection of BPA than oral
administration reflects the differences in
kinetics and bioavailability between these
two routes. The mean plasma concentration
of BPA in the sc 160 mg/kg BPA group was
much higher than in the group given the
same dose orally; this reﬂects the difference
in extent of uterotrophy resulting from the
two administration routes.
In this comparative study of the time-
course changes in BPA-induced uterotrophy,
the sensitivity to BPA as measured by both
uterine wet weight and relative weight was
higher at 6 or 24 hr after the last administra-
tion than at 12 and 18 hr. The percentage
increases in wet weight and relative weight of
40 and 160 mg/kg BPA groups at 6 hr was
higher than that at 24 hr relative to controls,
but the coefficient of variation for both
weights in the 8 mg/kg BPA group was lower
at 24 hr than at 6 hr. We therefore suggest
that autopsy at 24 hr after the last adminis-
tration is more suitable, based on the coefﬁ-
cient of variation at low dose levels. Reel et
al. (11) reported that uterine weights
increased until 6 hr after 17β -estradiol
administration and then decreased gradually;
uterine weights also increased at 24 hr. The
present results demonstrate that the OECD
recommendation for autopsy at 24 hr after
the last administration is reasonable for rat
utertrophic assays.
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Table 3. Plasma concentration of BPA 1 hr after
last administration.
Plasma
Dose concentration
Route (mg/kg) (ng/mL)
Subcutaneous Vehicle control ND
8 94.6 ± 58.0
40 886.3 ± 56.4
160 2948.8 ± 768.8
Oral Vehicle  control ND
40 ND
160 198.8 ± 88.2
800 2879.0 ± 2328.3
ND, not detected. Values shown are mean ± SD.
Table 4. Absolute uterine weights of rats 6, 12, 18, and 24 hr after last sc administration of BPA. 
Dose Wet weight  Blotted weight Wet weight  CV 
Hour (mg/kg/day) (mg)a (mg)a (% of control) (wet weight)
6 Vehicle control 27.8 ± 5.2 27.2 ± 5.0 100 18.7
8 36.5 ± 8.5* 34.9 ± 7.4* 131 23.2
40 55.6 ± 12.9** 53.4 ± 12.3** 200 23.2
160 75.9 ± 11.1** 72.5 ±10.8** 273 14.6
12 Vehicle control 28.9 ± 6.2 28.0 ± 6.1 100 21.4
8 32.2 ± 1.8 31.1 ± 1.7 111 5.5
40 50.1 ± 5.8** 48.6 ± 5.3** 173 11.6
160 63.4 ± 9.8** 62.0 ± 9.5** 219 15.4
18 Vehicle control 28.3 ± 4.7 27.3 ± 4.5 100 16.6
8 33.1 ± 5.3* 32.4 ± 5.4* 117 16.1
40 41.1 ± 5.6** 39.9 ± 5.4** 145 13.7
160 52.8 ± 7.4** 51.6 ± 7.0** 186 14.1
24 Vehicle control 27.6 ± 4.2 27.0 ± 4.1 100 15.2
8 36.6 ± 5.1** 35.7 ± 5.2** 133 14.1
40 40.1 ± 5.5** 39.4 ± 5.1** 146 13.7
160 53.5 ± 9.4** 52.3 ± 9.5** 194 17.7
CV, coefﬁcient of variation. 
aValues shown are mean ± SD. *Signiﬁcantly different from corresponding vehicle control at p < 0.05. **Signiﬁcantly dif-
ferent from corresponding vehicle control at p < 0.01.
Table 5. Relative uterine weights of rats 6, 12, 18 and 24 hr after last sc administration of BPA. 
Dose Wet weight  Blotted weight Wet weight  CV
Hour (mg/kg/day) (mg/100g)a (mg/100g)a (% of control) (wet weight)
6 Vehicle control 66.4 ± 8.1 65.0 ± 8.0 100 12.1
8 87.5 ± 18.2** 82.8 ± 15.8** 132 20.8
40 132.4 ± 23.3** 127.2 ± 22.0** 200 17.6
160 189.8 ± 25.8** 181.2 ± 25.8** 286 13.6
12 Vehicle control 66.4 ± 12.1 67.3 ± 11.4 100 18.2
8 78.0 ± 7.4 75.4 ± 6.7 112 9.4
40 122.2 ± 17.6** 118.5 ± 16.1** 176 14.4
160 152.2 ± 20.2** 148.8 ± 19.8** 219 13.3
18 Vehicle control 62.2 ± 10.9 59.8 ± 10.5 100 17.5
8 70.7 ± 8.8 69.2 ± 9.0* 114 12.5
40 87.3 ± 10.8** 84.8 ± 10.4** 140 12.4
160 115.7 ± 15.8** 113.0 ± 14.7** 186 13.7
24 Vehicle control 62.0 ± 7.1 60.7 ± 7.2 100 11.5
8 76.3 ± 12.2** 74.3 ± 12.4** 123 16.0
40 88.9 ± 10.5** 87.3 ± 9.8** 143 11.8
160 118.0 ± 19.4** 115.2 ± 19.5** 191 16.4
CV, coefﬁcient of variation. 
aValues shown are mean ± SD. *Signiﬁcantly different from corresponding vehicle control at p < 0.05. **Signiﬁcantly dif-
ferent from corresponding vehicle control at p < 0.01.REFERENCES AND NOTES
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